{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:22:00Z","timestamp":1794057720342,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally. Lecanemab, an FDA-approved amyloid beta (A\u03b2)-directed antibody indicated for the treatment of early AD, binds with high affinity to soluble A\u03b2 protofibrils, which have been shown to be more toxic to neurons than monomers or insoluble fibrils. Lecanemab has been shown to be well tolerated in multiple clinical trials, although risks include an increased rate of amyloid-related imaging abnormalities (ARIA) and infusion reactions relative to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clarity AD was an 18-month treatment (Core study), multicenter, double-blind, placebo-controlled, parallel-group study with open-label extension (OLE) in participants with early AD. Eligible participants were randomized 1:1 across 2 treatment groups (placebo and lecanemab 10\u00a0mg\/kg biweekly). Safety evaluations included monitoring of vital signs, physical examinations, adverse events, clinical laboratory parameters, and 12-lead electrocardiograms. ARIA occurrence was monitored throughout the study by magnetic resonance imaging, read both locally and centrally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 1795 participants from Core and 1612 participants with at least one dose of lecanemab (Core\u2009+\u2009OLE) were included. Lecanemab was generally well-tolerated in Clarity AD, with no deaths related to lecanemab in the Core study. There were 9 deaths during the OLE, with 4 deemed possibly related to study treatment. Of the 24 deaths in Core\u2009+\u2009OLE, 3 were due to intracerebral hemorrhage (ICH): 1 placebo in the Core due to ICH, and 2 lecanemab in OLE with concurrent ICH (1 on tissue plasminogen activator and 1 on anticoagulant therapy). In the Core\u2009+\u2009OLE, the most common adverse events in the lecanemab group (&gt;\u200910%) were infusion-related reactions (24.5%), ARIA with hemosiderin deposits (ARIA-H) microhemorrhages (16.0%), COVID-19 (14.7%), ARIA with edema (ARIA-E; 13.6%), and headache (10.3%). ARIA-E and ARIA-H were largely radiographically mild-to-moderate. ARIA-E generally occurred within 3\u20136 months of treatment, was more common in ApoE e4 carriers (16.8%) and most common in ApoE \u03b54 homozygous participants (34.5%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lecanemab was generally well-tolerated, with the most common adverse events being infusion-related reactions, ARIA-H, ARIA-E. Clinicians, participants, and caregivers should understand the incidence, monitoring, and management of these events for optimal patient care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov numbers: Clarity AD NCT03887455)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-024-01441-8","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:01:37Z","timestamp":1715317297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":194,"title":["Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Lawrence S.","family":"Honig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan N.","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"van Dyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Matta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Kanekiyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derk","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Dhadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Irizarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"1441_CR1","doi-asserted-by":"publisher","unstructured":"Alzheimer\u2019s A. 2023 Alzheimer\u2019s Disease Facts and Figures. Alzheimers Dement 2023;19(4). https:\/\/doi.org\/10.1002\/alz.13016. https:\/\/www.alz.org\/media\/documents\/alzheimers-facts-and-figures.pdf Accessed November 28, 2023.","DOI":"10.1002\/alz.13016"},{"key":"1441_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer\u2019s disease. Lancet. 2021;397:1577\u201390.","journal-title":"Lancet"},{"key":"1441_CR3","first-page":"15056","volume":"1","author":"C Masters","year":"2015","unstructured":"Masters C, Bateman R, Blennow K, et al. Alzheimer\u2019s disease. Nat Rev. 2015;1:15056.","journal-title":"Nat Rev"},{"key":"1441_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"2","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 2021;2:484\u201396.","journal-title":"Lancet Neurol"},{"key":"1441_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","volume":"8","author":"J Cummings","year":"2016","unstructured":"Cummings J, Aisen PS, DuBois B, et al. Drug development in Alzheimer\u2019s disease: the path to 2025. Alzheimers Res Ther. 2016;8:39.","journal-title":"Alzheimers Res Ther"},{"key":"1441_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.conb.2020.02.003","volume":"61","author":"DM Walsh","year":"2020","unstructured":"Walsh DM, Selkoe DJ. Amyloid \u03b2-protein and beyond: the path forward in Alzheimer\u2019s disease. Curr Opin Neurobiol. 2020;61:116\u201324.","journal-title":"Curr Opin Neurobiol"},{"key":"1441_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"1441_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13:80.","journal-title":"Alzheimers Res Ther"},{"key":"1441_CR9","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two Randomized phase 3 studies of Aducanumab in Early Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2022;9:197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"key":"1441_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"1441_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L S\u00f6derberg","year":"2023","unstructured":"S\u00f6derberg L, Johannesson M, Nygren P, et al. Lecanemab, Aducanumab, and Gantenerumab - binding profiles to different forms of amyloid-Beta might explain Efficacy and Side effects in clinical trials for Alzheimer\u2019s Disease. Neurotherapeutics. 2023;20:195\u2013206.","journal-title":"Neurotherapeutics"},{"key":"1441_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3233\/JAD-140741","volume":"43","author":"S Tucker","year":"2015","unstructured":"Tucker S, M\u00f6ller C, Tegerstedt K, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43:575\u201388.","journal-title":"J Alzheimers Dis"},{"key":"1441_CR13","doi-asserted-by":"publisher","first-page":"e32014","DOI":"10.1371\/journal.pone.0032014","volume":"7","author":"D Sehlin","year":"2012","unstructured":"Sehlin D, Englund H, Simu B, et al. Large aggregates are the major soluble A\u03b2 species in AD brain fractionated with density gradient ultracentrifugation. PLoS ONE. 2012;7:e32014.","journal-title":"PLoS ONE"},{"key":"1441_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000316530","volume":"8","author":"D Sehlin","year":"2011","unstructured":"Sehlin D, Hedlund M, Lord A, et al. Heavy-chain complementarity-determining regions determine conformation selectivity of anti-A\u03b2 antibodies. Neurodegener Dis. 2011;8:117\u201323.","journal-title":"Neurodegener Dis"},{"key":"1441_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JAD-130029","volume":"37","author":"K Magnusson","year":"2013","unstructured":"Magnusson K, Sehlin D, Syv\u00e4nen S, et al. Specific uptake of an Amyloid-\u03b2-Protofibril-binding antibody-Tracer in A\u03b2PP Transgenic Mouse Brain. J Alzheimer\u2019s Dis. 2013;37:29\u201340.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1441_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, et al. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14:191.","journal-title":"Alzheimers Res Ther"},{"key":"1441_CR17","doi-asserted-by":"publisher","first-page":"e12377","DOI":"10.1002\/trc2.12377","volume":"9","author":"LS Honig","year":"2023","unstructured":"Honig LS, Barakos J, Dhadda S, et al. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2023;9:e12377.","journal-title":"Alzheimers Dement (N Y)"},{"key":"1441_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid\u2010 modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367\u201385.","journal-title":"Alzheimers Dement"},{"key":"1441_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"1441_CR20","doi-asserted-by":"crossref","unstructured":"Jack CA Jr., Albert MS, Knopman DS et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement 2011;7;257\u2009\u2013\u200962.","DOI":"10.1016\/j.jalz.2011.03.004"},{"key":"1441_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11:241\u20139.","journal-title":"Lancet Neurol"},{"key":"1441_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1212\/WNL.0000000000008924","volume":"94","author":"R Waziry","year":"2020","unstructured":"Waziry R, Chibnik LB, Bos D, Ikram MK, Hofman A. Risk of hemorrhagic and ischemic stroke in patients with Alzheimer disease: a synthesis of the literature. Neurology. 2020;94:265\u201372.","journal-title":"Neurology"},{"key":"1441_CR23","unstructured":"LEQEMBI\u00ae (lecanemab-. irmb) injection, for intravenous use prescribing information.2023. Eisai Inc. Nutley, NJ, USA. Accessible at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269Orig1s001lbl.pdf Accessed November 28, 2023."},{"key":"1441_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, et al. Amyloid-Related Imaging Abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer Disease. JAMA Neurol. 2022;79:13\u201321.","journal-title":"JAMA Neurol"},{"key":"1441_CR25","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","volume":"73","author":"S Salloway","year":"2009","unstructured":"Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061\u201370.","journal-title":"Neurology"},{"key":"1441_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/JAD-220046","volume":"87","author":"E Lacorte","year":"2022","unstructured":"Lacorte E, Ancidoni A, Zaccaria V, et al. Safety and Efficacy of Monoclonal antibodies for Alzheimer\u2019s Disease: a systematic review and Meta-analysis of published and unpublished clinical trials. J Alzheimers Dis. 2022;87:101\u201329.","journal-title":"J Alzheimers Dis"},{"key":"1441_CR27","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023. https:\/\/doi.org\/10.14283\/jpad.2023.30","journal-title":"J Prev Alzheimers Dis"},{"key":"1441_CR28","doi-asserted-by":"publisher","unstructured":"Ramanan VK, Armstrong MJ, Choudhury P, et al. Antiamyloid monoclonal antibody therapy for Alzheimer Disease: emerging issues in Neurology. Neurology. 2023 Jul;26. https:\/\/doi.org\/10.1212\/WNL.0000000000207757","DOI":"10.1212\/WNL.0000000000207757"}],"updated-by":[{"DOI":"10.1186\/s13195-024-01507-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000}}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01441-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01441-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01441-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T02:03:32Z","timestamp":1720663412000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01441-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1441"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01441-8","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13195-024-01507-7","URL":"https:\/\/doi.org\/10.1186\/s13195-024-01507-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved by the institutional review board or independent ethics committee at each center and all participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LSH receives research funding from Abbvie, Acumen, Alector, Biogen, Bristol-Myers Squibb, Cognition, EIP, Eisai, Ferrer, Genentech\/Roche, Janssen\/J&J, Transposon, UCB, Vaccinex. LSH is a consultant for Alector, Biogen, Cortexyme, Eisai, Medscape, and Prevail\/Lilly.MNS has ownership interest (Stock or stock options): NeuroTau, uMethod Health, Versanum, Athira, TransDermix, Seq BioMarque, NeuroReserve, Cortexyme\/Quince Therapeutics, Lighthouse Therapeutics. MNS is a consultant for: Alzheon, Biogen, Roche-Genentech, Eisai, KeifeRx, Lilly, Synaptogenix, NeuroTherapia, T3D, Signant Health, Novo Nordisk. MNS receives royalties from Humanix. MNS is a Board of Director for EIP Pharma.CHvD is a consultant for Roche, Eisai, Cerevel, and Ono and receives research support from Biogen, Eisai, Roche, Genentech, Eli Lilly, Janssen, UCB, Cerevel, and Biohaven.RAS is a consultant to: AbbVie, AC Immune, Acumen, Alector, Bristol-Myers Squibb, Genentech, Ionis, Janssen, Oligomerix, Prothena, Roche, Shionogi. RAS receives research funding from the National Institute on Aging (P01AG036694; R01AG054029; R01AG061848, U24AG057437; R01 AG03689), the Alzheimer\u2019s Association, GHR Foundation, Eli Lilly, Eisai \u2013 Public-Private Partnership Trial Funding, and. Accelerating Medicines Partnership FNIH.SH, AM, LG, MG, MK, DL, SD, MI, and LK are employees of Eisai.DP is an employee of Clario.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}